A phase II trial of oral temozolomide in patients with metastatic renal cell cancer

D. Park, Christopher Ryan, M. Dolan, N. Vogelzang, W. Stadler

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Purpose: To determine the activity of temozolomide, an oral imidazotetrazine alkylating agent that has exhibited broad antitumor activity in preclinical studies, in renal cell cancer (RCC) patients. Methods: Metastatic RCC patients were treated with temozolomide, 200 mg/m2 per day orally, and traditional radiologic response endpoints were assessed. O6-Alkylguanine-DNA alkyltransferase (AGT) activity was measured in four pretreatment biopsies. Results: Among 12 patients, there were no responses. High AGT activity was observed in all four biopsies analyzed. Conclusions: Temozolomide is not active against RCC and this clinical observation may be due to high levels of AGT in this tumor.

Original languageEnglish (US)
Pages (from-to)160-162
Number of pages3
JournalCancer Chemotherapy and Pharmacology
Volume50
Issue number2
DOIs
StatePublished - 2002
Externally publishedYes

Fingerprint

temozolomide
Renal Cell Carcinoma
Biopsy
Alkylating Agents
Tumors
Observation
Neoplasms

Keywords

  • DNA repair
  • O-Alkylguanine-DNA alkyltransferase
  • Phase II trial
  • Renal cell cancer

ASJC Scopus subject areas

  • Cancer Research
  • Pharmacology
  • Oncology

Cite this

A phase II trial of oral temozolomide in patients with metastatic renal cell cancer. / Park, D.; Ryan, Christopher; Dolan, M.; Vogelzang, N.; Stadler, W.

In: Cancer Chemotherapy and Pharmacology, Vol. 50, No. 2, 2002, p. 160-162.

Research output: Contribution to journalArticle

Park, D. ; Ryan, Christopher ; Dolan, M. ; Vogelzang, N. ; Stadler, W. / A phase II trial of oral temozolomide in patients with metastatic renal cell cancer. In: Cancer Chemotherapy and Pharmacology. 2002 ; Vol. 50, No. 2. pp. 160-162.
@article{68691bab192944fcab846f4ad2773d16,
title = "A phase II trial of oral temozolomide in patients with metastatic renal cell cancer",
abstract = "Purpose: To determine the activity of temozolomide, an oral imidazotetrazine alkylating agent that has exhibited broad antitumor activity in preclinical studies, in renal cell cancer (RCC) patients. Methods: Metastatic RCC patients were treated with temozolomide, 200 mg/m2 per day orally, and traditional radiologic response endpoints were assessed. O6-Alkylguanine-DNA alkyltransferase (AGT) activity was measured in four pretreatment biopsies. Results: Among 12 patients, there were no responses. High AGT activity was observed in all four biopsies analyzed. Conclusions: Temozolomide is not active against RCC and this clinical observation may be due to high levels of AGT in this tumor.",
keywords = "DNA repair, O-Alkylguanine-DNA alkyltransferase, Phase II trial, Renal cell cancer",
author = "D. Park and Christopher Ryan and M. Dolan and N. Vogelzang and W. Stadler",
year = "2002",
doi = "10.1007/s00280-002-0473-z",
language = "English (US)",
volume = "50",
pages = "160--162",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "2",

}

TY - JOUR

T1 - A phase II trial of oral temozolomide in patients with metastatic renal cell cancer

AU - Park, D.

AU - Ryan, Christopher

AU - Dolan, M.

AU - Vogelzang, N.

AU - Stadler, W.

PY - 2002

Y1 - 2002

N2 - Purpose: To determine the activity of temozolomide, an oral imidazotetrazine alkylating agent that has exhibited broad antitumor activity in preclinical studies, in renal cell cancer (RCC) patients. Methods: Metastatic RCC patients were treated with temozolomide, 200 mg/m2 per day orally, and traditional radiologic response endpoints were assessed. O6-Alkylguanine-DNA alkyltransferase (AGT) activity was measured in four pretreatment biopsies. Results: Among 12 patients, there were no responses. High AGT activity was observed in all four biopsies analyzed. Conclusions: Temozolomide is not active against RCC and this clinical observation may be due to high levels of AGT in this tumor.

AB - Purpose: To determine the activity of temozolomide, an oral imidazotetrazine alkylating agent that has exhibited broad antitumor activity in preclinical studies, in renal cell cancer (RCC) patients. Methods: Metastatic RCC patients were treated with temozolomide, 200 mg/m2 per day orally, and traditional radiologic response endpoints were assessed. O6-Alkylguanine-DNA alkyltransferase (AGT) activity was measured in four pretreatment biopsies. Results: Among 12 patients, there were no responses. High AGT activity was observed in all four biopsies analyzed. Conclusions: Temozolomide is not active against RCC and this clinical observation may be due to high levels of AGT in this tumor.

KW - DNA repair

KW - O-Alkylguanine-DNA alkyltransferase

KW - Phase II trial

KW - Renal cell cancer

UR - http://www.scopus.com/inward/record.url?scp=0036351280&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036351280&partnerID=8YFLogxK

U2 - 10.1007/s00280-002-0473-z

DO - 10.1007/s00280-002-0473-z

M3 - Article

VL - 50

SP - 160

EP - 162

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 2

ER -